Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters
- Авторлар: Zabotina T.1, Korotkova O.1, Chertkova A.1, Zakharova E.1, Tabakov D.1, Dzhgamadze N.1, Savostikova M.1, Artamonova E.1, Khailenko V.1, Kovalenko E.1, Kadagidze Z.1
-
Мекемелер:
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- Шығарылым: Том 166, № 2 (2018)
- Беттер: 241-244
- Бөлім: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/240929
- DOI: https://doi.org/10.1007/s10517-018-4323-3
- ID: 240929
Дәйексөз келтіру
Аннотация
In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16+ lymphocytes and a negative correlation of this parameter with the number of regulatory CD4+CD25+CD127— cells and proliferative activity of Ki-67 tumor cells were revealed. Higher level of Ki-67 was associated with reduced number of effector lymphocytes (CD8+ and CD16+) and elevated content of regulatory CD8+CD11b—CD28— T cells. The absence of expression of estrogen receptors was associated with reduced cytotoxic potential of CD8+ T cell in comparison with ER+ breast cancer. The percentage of CD8+ lymphocytes (CD3+CD8+ and CD8+CD11b+CD28+) among lymphocytes infiltrating the tumor was higher in PR+ breast cancer than in PR— tumors. With increasing the tumor load, the number of lymphocytes expressing CD16 marker and their cytotoxic potential decreased.
Авторлар туралы
T. Zabotina
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Хат алмасуға жауапты Автор.
Email: tatzabotina@yandex.ru
Ресей, Moscow
O. Korotkova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
A. Chertkova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
E. Zakharova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
D. Tabakov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
N. Dzhgamadze
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
M. Savostikova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
E. Artamonova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
V. Khailenko
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
E. Kovalenko
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
Z. Kadagidze
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: tatzabotina@yandex.ru
Ресей, Moscow
![](/img/style/loading.gif)